 "Lupin soars on USFDA nod for Fenofibrate tablets")
Shares of Lupin are trading higher by 5.6% to Rs 1,896 on the Bombay Stock Exchange (BSE) after the pharma major said it has received approval from USFDA for Fenofibrate tablets in dosages of 160 mg and 54 mg.
Fenofibrate is mainly used to reduce cholesterol levels in patients at risk of cardiovascular disease. Like other fibrates, it reduces both low-density lipoprotein (LDL) and very low density lipoprotein (VLDL) levels, as well as increasing high-density lipoprotein (HDL) levels and reducing triglyceride levels.
The stock opened at Rs 1,820 and touched a high of Rs 1,898 on the BSE. A total of 126,821 shares have changed hands on the BSE so far.